Infographic: Adalimumab Approvals in the United States and European Union

Competition for the $16 billion market for Humira is heating up with new approvals for adalimumab biosimilars in the United States and European Union.

Competition for the $16 billion market for Humira is heating up with new approvals for adalimumab biosimilars in the United States and European Union.

Related Content:

BusinessRegulatoryRheumatology
Can Global Policies to Boost Biosimilar Adoption Work in the US?
Overcoming Challenges to Improve Access and Reduce Costs
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD